Dual Activation of Phospholipase C-ϵ by Rho and Ras GTPases by Seifert, Jason P. et al.
Dual Activation of Phospholipase C- by Rho and
Ras GTPases*
Received for publication, July 2, 2008, and in revised form, August 25, 2008 Published, JBC Papers in Press, September 2, 2008, DOI 10.1074/jbc.M805038200
Jason P. Seifert‡, Yixing Zhou‡, Stephanie N. Hicks‡, John Sondek‡§¶, and T. Kendall Harden‡§1
From the ‡Department of Pharmacology, the §Lineberger Comprehensive Cancer Center, and the ¶Department of Biochemistry
and Biophysics, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599
Phospholipase C- (PLC-) is a highly elaborated PLC
required for a diverse set of signaling pathways. Here we use a
combinationof cellular assays and studieswithpurifiedproteins
to show that activated RhoA and Ras isoforms directly engage
distinct regions of PLC- to stimulate its phospholipase activity.
Purified PLC- was activated in a guanine nucleotide- and
concentration-dependent fashion by purified lipidated K-Ras
reconstituted in PtdIns(4,5)P2-containing phospholipid vesi-
cles.Whereasmutation of two critical lysine residues within the
second Ras-association domain of PLC- prevented K-Ras-de-
pendent activation of the purified enzyme, guanine nucleotide-
dependent activation by RhoA was retained. Deletion of a loop
unique to PLC- eliminated its activation by RhoA but not
H-Ras. In contrast, removal of the autoinhibitory X/Y-linker
region of the catalytic core of PLC- markedly activates the
enzyme (Hicks, S. N., Jezyk, M. R., Gershburg, S., Seifert, J. P.,
Harden, T. K., and Sondek, J. (2008)Mol. Cell, 31, 383–394), but
PLC- lacking this regulatory region retained activation by both
Rho and Ras GTPases. Additive activation of PLC- by RhoA
and K- or H-Ras was observed in intact cell studies, and this
additivity was recapitulated in experiments in which activation
of purified PLC- was quantified with PtdIns(4,5)P2-containing
phospholipid vesicles reconstitutedwith purified, isoprenylated
GTPases. A maximally effective concentration of activated
RhoA also increased the sensitivity of purified PLC- to activa-
tion by K-Ras. These results indicate that PLC- can be directly
and concomitantly activated by both RhoA and individual Ras
GTPases resulting in diverse upstream control of signaling cas-
cades downstream of PLC-.
Activation of receptors by a variety of hormones, neurotrans-
mitters, growth factors, and other extracellular signaling mole-
cules promotes activation of inositol lipid-specific phospho-
lipase C (PLC)2 enzymes to catalyze hydrolysis of PtdIns(4,5)P2
into diacylglycerol and inositol (1,4,5)-trisphosphate (1). These
second messenger molecules are responsible for the stimula-
tion of protein kinase C isozymes and themobilization of intra-
cellular Ca2, respectively (2, 3). PLC-catalyzed depletion of
cellular PtdIns(4,5)P2 also provides regulation of many addi-
tional cellular events. For example, a broad range of proteins
contain structural domains, including PH, FERM, ENTH, and
PX domains, that specifically bind inositol lipids necessary for
their function (4, 5), and PtdIns(4,5)P2-binding proteins are
implicated in a broad range of cell signaling events including
membrane trafficking, changes in the actin cytoskeleton, and
ion channel and transporter function (5).
The six PLC subfamilies (PLC-, -, -, -, -, and -) all
contain conserved X- and Y-regions, which fold cooperatively
to form a catalytic triose-phosphate isomerase (TIM) barrel.
Elaboration of the catalytic core with various protein binding
and/or regulatory domains gives rise to multiple modes of reg-
ulation and different PLC subfamilies. PLC- isozymes are acti-
vated by heterotrimeric G subunits of the Gq family (6–8), by
G subunits (9–11), and by the small GTPase Rac (12–15).
The region linking the catalytic X- and Y-boxes of PLC- iso-
forms encompass a split PH domain, two SH2 domains, and an
SH3 domain, and is subject to activation by tyrosine phospho-
rylation (16–18).More recently, RacGTPases have been shown
to specifically activate PLC-2, but not PLC-1 (19). The
recently identified PLC-2 is directly activated by G sub-
units (20, 21). The regulation of PLC- (22, 23) and PLC- (24,
25) is less well understood, although both are relatively sensi-
tive to changes in cytosolic calcium concentration compared
with other PLC isozymes.
The sixth family member of PLC isozymes, PLC-, was ini-
tially identified inCaenorhabditis elegans as a Ras-binding pro-
tein (26). Subsequent cloning of the mammalian homolog of
PLC- confirmed the presence of conserved Ras-interacting
domains, including tandem C-terminal RA domains and an
N-terminal CDC25 domain that imparts guanine nucleotide
exchange activity to the protein (27–29). Co-expression of con-
stitutively active Ras family GTPases, including Ras and Rap
family members, with PLC- results in an increased cellular
accumulation of inositol phosphates (29–32). Co-expression of
PLC- with G12, G13 (28, 33), or G (30) also promotes
increased phospholipase activity in COS-7 cells. Finally, our
studies with PLC- coexpressed with Rho family GTPases (33),
as well as experiments with purified proteins (34), indicate that
PLC- is a direct effector of RhoA, RhoB, and RhoC.
Although many effectors of Ras, Rho, and Rac GTPases have
been identified, knowledge of signaling proteins directly regu-
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lated by multiple GTP-bound GTPases through interactions
with distinct regulatory domains is limited. Therefore, the goals
of this study were to establish incontrovertible evidence for
direct and dual regulation of PLC- by Rho and Ras family
GTPases, to confirm that Rho and Ras interact with distinct
regions of PLC-, and to delineate the consequences of simul-
taneous activation of a single PLC isozyme by two GTP-bound
activators. Dual, simultaneous, and additive regulation of
PLC- is illustrated, and our biochemical studies have revealed
that GTP-bound RhoA increases the sensitivity of PLC- to
activation by K-Ras.
EXPERIMENTAL PROCEDURES
Materials—The open reading frame of rat PLC- in pCMV
script was a kind gift from Grant Kelley, State University of New
York, Syracuse, NY. The expression vector for GFP-RhoA was a
kind gift from Keith Burridge, University of North Carolina,
Chapel Hill, NC. Hemagglutinin A-tagged and 63L and 12V
GTPase-deficient mutants of Ras-family GTPases were obtained
from the Guthrie Institute (Sayre, PA). His6-tagged TEV protease
was purified as previously described (35). K-Ras-4B was the form
of K-Ras used in intact cell studies and for protein purification.
Construction of Mammalian PLC- Expression Vectors—
PLC- fragments were constructed as previously described
(33). Briefly, full-length rat PLC- cDNA was used as a tem-
plate, and PCR was applied to amplify the selected regions fol-
lowing standard protocols. The resulting amplified products
were ligated in-frame into pCMV-myc (Clontech). Constructs
were confirmed by sequencing. The specific constructs used
and ranges of amino acid residues included in each construct
were as follows: CDC25-Ct, 509–2281; CDC25-RA1,
509–2113; EF-RA2, 1198–2215; and EF-Ct, 1198–2281;
EF-Ct-Y, 1198–2281 lacking residues 1667–1728; EF-Ct-
linker 1198–2281 lacking residues 1532–1641.
Transfection of COS-7 Cells and Quantification of Inositol
Phosphate Accumulation—COS-7 cells weremaintained in high
glucoseDulbecco’smodified Eagle’smedium containing 10% fetal
bovine serum, 100 units/ml penicillin, and 100 g/ml streptomy-
cin at 37 °C in an atmosphere of 90% air/10% CO2. Cells were
seeded in 12-well culture dishes at a density of 65,000 cells per
well 24 h prior to transfection. The indicated DNA vectors were
transfectedusingFuGENE6 (RocheAppliedScience) transfection
reagent according to the manufacturer’s protocol. The total
amountof transfectedDNAwas700ngand includedemptyvector
to maintain an equal amount of DNA per well. The culture
medium was changed 24 h after transfection to inositol-free
Dulbecco’s modified Eagle’s medium (ICN Biomedicals) contain-
ing 1 Ci/well myo-[2-3H(N)]inositol (American Radiolabeled
Chemicals). Metabolic labeling was allowed to proceed for 12–18
h. Accumulation of 3H-labeled inositol phosphates were quanti-
fied following a 60-min incubation in the presence of the 10 mM
LiCl to inhibit inositol phosphate phosphatases. Incubations were
terminated by aspiration of the culture medium and subsequent
addition of 50mM formic acid followed by neutralizationwith 150
mM NH4OH. [3H]Inositol phosphates were isolated and quanti-
fied using Dowex chromatography as described previously (36).
Variability in cpm of [3H]inositol phosphate accumulation across
experiments occurred due to differences in the amount of
[3H]inositol used for labeling, duration of the prelabeling period,
or different amounts of DNA used for transfection.
Coimmunoprecipitation of PLC- with Ras and Rho GTPases
fromCOS-7Cells—Cells were seeded in 10-cm culture dishes at
a density of 1 million cells per dish 24 h prior to transfection.
The indicated DNA vectors were transfected using FuGENE 6
transfection reagent according to the manufacturer’s protocol.
The total amount of transfected DNA was 14 g and included
empty vector to maintain an equal amount of DNA per dish.
The culture medium was changed 24 h after transfection to
serum-free Dulbecco’s modified Eagle’s medium (Invitrogen).
15 h after serum starvation, cells were washed twice with ice-
cold PBS and once with 10 mM Hepes, pH 7.4. Cells were incu-
bated in 1ml of hypotonic lysis buffer (10mMHepes, pH 7.4, 10
mM NaCl, 5 mM MgCl2, 1 mM EDTA, and protease inhibitor
mixture) for 15 min on ice with rocking. Cells were collected
with a cell scraper, Dounce-homogenized (20 strokes), and
passed through a 27-gauge needle (3 times). Crude membrane
preparations were isolated by centrifuging whole cell lysates
(40,000 g, 1 h, 4 °C) using a table-top ultracentrifuge (TLA 55
rotor). The membrane pellet was resuspended in 500 l of lysis
buffer (above)  1% Triton X-100  protease inhibitor mix-
ture, and Dounce-homogenized (30 strokes). Membrane
samples were precleared with protein A/G beads at 4 °C for
1 h. Precleared samples were incubated with 2.5 g anti-Myc
9E10 antibody (Roche Applied Science) and protein A/G
beads (Santa Cruz Biotechnology) at 4 °C for 3 h. Beads were
collected by centrifugation at 13,800  g for 1 min and
washed three times with hypotonic lysis buffer  protease
inhibitor mixture. Immunoprecipitated samples were eluted
by incubating with 2 Lammeli buffer at room temperature
for 30 min, and all samples were boiled prior to SDS-PAGE
and immunoblot analysis.
Purification of PLC Constructs—PLC--EF-RA2 (amino
acids 1258–2215) was amplified from full-length rat PLC- and
subcloned into NcoI/XhoI-digested pFastBacHT, which incor-
porates an N-terminal hexahistidine tag and TEV protease site
for cleavage of the affinity tag. Site-directed mutagenesis was
used to generate PLC--EF-RA2(KE), a construct with muta-
tions of lysine residues 2150 and 2152 to glutamic acid. Bacu-
loviruses encoding each PLC- construct were generated using
the Bac-to-Bac method per the manufacturer’s instructions
(Invitrogen).
PLC--EF-RA2 and PLC--EF-RA2(KE) were purified as
follows. HighFive cells were grown in 4 liter shaker flasks at
27 °C to a density of2.0 106 cells/ml and infectedwith virus
encoding PLC--EF-RA2 or PLC--EF-RA2(KE) at a multi-
plicity of infection of 1.0. Cells were harvested 48 h after infec-
tion by low speed centrifugation and resuspended to a final
volume of 150 ml in buffer A (20 mM HEPES, pH 8.0, 300 mM
NaCl, 1mMCaCl2, 10% glycerol, and EDTA-freeComplete pro-
tease inhibitor tablets (Roche Applied Science)). The resus-
pended cells were lysed by passage through an EmulsiFlex C5
homogenizer (Avestin). Intact cells and nuclei were removed
from the lysate by low speed centrifugation at 500  g for 15
min. The supernatant from the low-speed centrifugation was
clarified by centrifugation at 100,000  g for 1 h. The resulting
supernatant was diluted to a final volume of 150 ml and loaded
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onto a 5-ml HisTrap metal chelate column (GE Healthcare)
charged with Ni2. The loaded column was washed with 10
column volumes of buffer A, followed by a 10 column volumes,
3% buffer B wash (buffer A  1 M imidazole). Recombinant
protein was eluted using a 3–50% buffer B linear gradient over
20 column volumes collecting 5-ml fractions. Fractions con-
taining recombinant protein were pooled, and hexahistidine-
tagged TEV protease was added to the sample to cleave the
hexahistidine tag from the PLC- fragment. The sample was
dialyzed overnight against buffer A to remove the imidazole.
The cleaved PLC- fragment was subjected to a second passage
over aNi2-charged 1-mlHisTrap column, and the proteinwas
eluted with buffer containing 5 mM imidazole, which separates
the cleaved PLC- fragment from the hexahistidine tag and
TEV protease. Fractions containing the recombinant protein
were pooled and concentrated using a 50,000MWCOPES cen-
trifugal filtering device (Sartorius). Typical yields for PLC--EF-
RA2 and PLC--EF-RA2(KE)were1mg per liter of infected
cells.
Purification of Monomeric GTPases—Coding sequences for
full-length humanmonomeric GTPases were amplified by PCR
and ligated into BamHI/XhoI-digested pFastBacHT, which
incorporates an N-terminal hexahistidine tag. Baculoviruses of
each GTPase were produced using the Bac-to-Bac system per
the manufacturer’s protocol. HighFive cells at a density of
2.0  106 cells/ml were infected with baculovirus at a multi-
plicity of infection of 1.0. Cells were harvested 48 h after
infection by low speed centrifugation and resuspended in a final
volume of 100 ml of buffer A (20 mM HEPES, pH 8.0, 150 mM
NaCl, 1 mM MgCl2, 5% glycerol, 1 mM dithiothreitol, one
EDTA-free Complete protease inhibitor tablet). Cells were
lysed using an Emulsiflex C5 homogenizer. Cell lysates were
cleared of intact cells and nuclei by low speed centrifugation at
500  g for 15 min. Membranes of virus-infected cells were
harvested from the resulting supernatant by high speed centrif-
ugation at 100,000  g for 1 h. Post-translationally modified,
membrane-bound GTPases were extracted from the harvested
membranes after resuspension in buffer A containing 1%
sodium cholate and one EDTA-free Complete protease inhibi-
tor at a final protein concentration of 5 mg/ml. Resuspended
membranes were subjected to rapid stirring for 1 h at 4 °C.
Solubilized membrane proteins were separated from the par-
ticulate fraction by centrifugation at 100,000  g for 1 h.
Ni-NTA agarose (Qiagen) was added to the resulting super-
natant and incubated for 1 h at 4 °C. The resulting slurry mix-
ture was added to a gravity flow column and washed with 10
columnvolumes (CV) of bufferA containing 500mMNaCl. The
column was then equilibrated with buffer A containing 10 mM
NaCl, and recombinant protein was eluted in 10 CV of buffer B
(20 mM HEPES, pH 8.0, 10 mM NaCl, 1 mM MgCl2, 400 mM
imidazole, 5% glycerol, 0.5% sodium cholate). Sample contain-
ing the eluted protein was diluted to 50 ml in buffer B and
applied to a 1 ml HiTrap Q column (GE Healthcare). The
loaded column was washed with 10 CV of buffer B, and protein
was eluted using a linear NaCl gradient from 10 to 500mM over
25 CV. Fractions containing the recombinant protein were
pooled and applied directly to a 1-ml HisTrap column (GE
Healthcare) charged with Ni2. The loaded column was
washed with 10 CV of buffer C (20 mMHEPES, pH 8.0, 150 mM
NaCl, 1 mM MgCl2, 0.5% sodium cholate, 5% glycerol) and 10
CV of 5% buffer D (buffer C  1 M imidazole). Protein specifi-
cally bound to the column was eluted with a 0 to 50% buffer D
gradient over 20 CV collecting 1 ml fractions. Fractions con-
taining recombinant GTPase were pooled and concentrated
using a 10,000 MWCO PES centrifugal filtering device (Sarto-
rius). All steps were completed within 1 day with no freezing of
the sample between column purifications. The concentrations
of the individual GTPases were determined by quantifying the
binding of [35S]GTPS under identical buffer and assay condi-
tions described below for reconstitution of the GTPases with
phospholipid vesicles. The ability of purified, lipidatedGTPases
to associate with phospholipid vesicles was tested as previously
described (37).
Phospholipase C Reconstitution Assay—Experiments to
determine regulation of PLC activity by G proteins were per-
formed as previously described with minor modifications (34,
38). Briefly, phospholipid vesicles were created by combining
600 M PE (Avanti Polar Lipids), 50 M PtdIns(4,5)P2 (Perkin
Elmer), and 10,000 cpm of [3H]PtdIns(4,5)P2 (Perkin Elmer)
per assay into a glass borosilicate tube and drying the mixture
under a stream of nitrogen. Vesicles were created by resuspen-
sion of the dried lipids in 20 mM HEPES, pH 7.4, followed by
probe sonication. Assayswere performed in a final volume of 60
l in a reaction mixture containing 20 mM HEPES, pH 7.4, 70
mM KCl, 3 mM EGTA, 2 mM dithiothreitol, 0.16 mg/ml fatty
acid-free bovine serum albumin, 10M free calcium, and 0.03%
sodium cholate. Purified GTPases were diluted 6-fold into the
assay. The GTPases were loaded with nucleotide in the absence
of PLC by incubating the G protein/lipid suspension for 30min
at 30 °C with 10 M GDP or 10 M GTPS. Reactions were
initiated by the addition of purified PLC and incubations were
at 30 °C for 5–10 min as indicated in the figure legends. Reac-
tions were terminated by the addition of 200 l of 10% trichlo-
roacetic acid and 100 l of 10 mg/ml fatty acid-free bovine
serum albumin. Soluble [3H]inositol phosphates were quanti-
fied by liquid scintillation counting of the soluble fraction after
centrifugation of the reaction mixture.
Data Analysis—All experiments were carried out at least
three times with duplicate or triplicate samples in each experi-
ment. Results are presented as representative or pooled data
sets. Dose-response curves were generated using GRAPHPAD
PRISM software (Graphpad Software Inc., San Diego, CA). Sta-
tistical significance was assessed with a Student’s t test.
RESULTS
Activation of PLC- by Rho and Ras—To establish evidence
for dual and simultaneous regulation of PLC- by Rho and Ras
GTPases, the capacity of GTPases to interact with PLC- in
intact cells was tested in pull-down assays using antibody
directed against a c-Myc tag on the N terminus of PLC-.
Expression of PLC- with either GTPase-deficient RhoA or
K-Ras resulted in PLC--dependent pull-down of the GTPase
from membrane extracts of these cells (Fig. 1A). Moreover,
both RhoA and K-Ras were pulled down from membrane
extracts of cells expressing both GTPases with PLC-. The
amount of RhoA interacting with PLC- in cells expressing
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RhoA andK-Ras simultaneouslywas greater than that observed
in samples fromcells expressing only RhoAwith PLC-, and the
amount of K-Ras pulled down in cells expressing RhoA and
K-Ras simultaneously was at least as great as that observed in
samples from cells expressing only K-Ras with PLC- (Fig. 1A).
The relative capacity of both Ras and Rho GTPases to acti-
vate PLC- also was examined in COS-7 cells transiently trans-
fected with DNA encoding GTPase-deficient G-proteins and
PLC-. Whereas expression of H-Ras or K-Ras (Fig. 1B) or
N-Ras (data not shown) alone had no effect on [3H]inositol
phosphate accumulation, marked accumulation occurred
when theseGTPaseswere coexpressedwith PLC-, and data for
the effects of maximally effective amounts of Ras GTPases are
illustrated in Fig. 1B. We previously demonstrated that RhoA
directly activates PLC- (33, 34), and the amount of PLC--de-
pendent accumulation of [3H]inositol phosphates was similar
with maximally effective amounts of GTPase-deficient RhoA
and K-Ras or H-Ras (Fig. 1B). Maximally activating amounts of
RhoA and K-Ras or H-Ras also were simultaneously expressed
with PLC- in COS-7 cells. Co-expression of RhoA with either
K-Ras or H-Ras resulted in PLC--dependent inositol phos-
phate accumulation significantly greater than that observed
after expression of either GTPase individually. The effect of
coexpression of PLC- with both RhoA and K-Ras (or H-Ras)
ranged from a partially additive effect as shown in Fig. 1B to a
fully additive effect (data not shown). In contrast, co-expression
of maximally effective concentrations of H-Ras with K-Ras
resulted in no additivity of PLC--dependent response (data
not shown).Western blots confirmed that the levels of GTPase
or PLC- expression from the indicated amounts of DNA were
not changed by co-expression with various other expression
vectors (data not shown).
Our previous studies suggested that Rho and Ras GTPases
regulate the activity of PLC- through specific and separate
regions of the enzyme (33). These observations were extended
by a series of experiments inCOS-7 cells transiently transfected
with DNA encoding GTPase-deficient RhoA or H-Ras with
various constructs of PLC- (Fig. 2A). Activity observed with
PLC- lacking the N-terminal region (CDC25-Ct) was mark-
edly increased by co-expression with either RhoA or H-Ras
(Fig. 2B). As previously illustrated (32), removal of the second
RA domain of PLC- resulted in an isozyme (CDC25-RA1) that
was not activated by H-Ras; however, this construct retained
capacity for RhoA-dependent activation (Fig. 2B). PLC- lack-
ing an insertion within the Y-box (EF-Ct-Y) that is unique to
PLC- isozymes (30) was not activated by co-expression with
RhoA; however, removal of the Y-box insert did not affect the
ability of PLC- to be regulated by H-Ras (Fig. 2B).
Our recent structural and biochemical studies exploring the
mechanism whereby Rac1 activates PLC-2 have implicated
the poorly conserved X/Y-linker region of the catalytic core of
PLC isozymes in regulation of their activity (15, 39). These
studies indicated that the X/Y-linker region of PLC-2 and
potentially other PLC isozymes subserves an autoinhibitory
function, and removal of this region results in activation of
PLC-2 as well as other isozymes. For example, removal of this
region of PLC- results in a 10–100-fold increase in basal
enzyme activity as compared with wild-type PLC- when
expressed in COS-7 cells (39). To determine whether PLC-
lacking the X/Y-linker region retains activation by Rho and Ras
GTPases, a fragment of PLC- lacking this region (PLC--EF-
Ct-linker) was co-expressed with RhoA and H-Ras in COS-7
cells. As illustrated in Fig. 2B, PLC--EF-Ct-linker retained
capacity for activation by RhoA and H-Ras when co-expressed
with either of these GTPases.
FIGURE 1. G protein activation of PLC- in cells overexpressing GTPases.
A, COS-7 cells were transfected with an expression vector for Myc-PLC--EF-Ct
(6 g) in the absence or presence of constitutively active HA-K-Ras (4 g),
GFP-RhoA (4 g), or with both HA-K-Ras (4 g) and GFP-RhoA (4 g). Samples
were immunoprecipitated using anti-Myc 9E10 antibody as described in
“Experimental Procedures,” and the samples were immunoblotted with anti-
Myc 9E10 (Roche Applied Science) for PLC-, anti-GFP-HRP (Santa Cruz Bio-
technology) for RhoA, and anti-HA-HRP 3F10 (Roche Applied Science) for
K-Ras. Data shown are representative of three individual experiments. B, full-
length Myc-PLC- (50 ng) was expressed alone in COS-7 cells, or expressed
with different combinations of RhoA (30 ng), H-Ras (30 ng), or K-Ras (30 ng), as
indicated. [3H]Inositol phosphate accumulation was quantified as described
under “Experimental Procedures.” [3H]Inositol phosphate accumulation
observed with empty vector alone was subtracted from each value. The data
shown are the mean  S.D. for triplicate samples and are representative of
results from three or more experiments in each case.
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Selective G Protein-mediated Regulation of Purified PLC-—
Experiments also were carried out to begin to address unequiv-
ocally the idea that PLC- is a direct effector of both Rho and
Ras GTPases independently regulating the isozyme through
separate binding surfaces. Ras superfamily G proteins were
overexpressed in HiFive insect cells, detergent-extracted from
isolated membranes, and purified to homogeneity as described
under “Experimental Procedures.” K-Raswas used as themodel
RasGTPase in these studies because, aswas the casewithRhoA,
it was readily purified (see Fig. 4, top panel) in ample amounts in
a form that bound [35S]GTPS stoichiometrically and associ-
atedwith reconstituted substrate-containing phospholipid ves-
icles as described in “Experimental Procedures.” In contrast,
attempts to generate pure, active H-Ras in a form that repro-
ducibly and quantitatively associated with phospholipid vesi-
cles were unsuccessful.
Various concentrations of purified K-Ras were reconstituted
in [3H]PtdIns(4,5)P2 substrate-containing phospholipid vesi-
cles, and the capacity of this GTPase to activate purified PLC-
was quantified. Whereas little effect of K-Ras was observed in
the presence of GDP, marked concentration-dependent stimu-
lation occurred with K-Ras activated with GTPS (Fig. 3). The
extent of GTPS-dependent activation (2–6 times greater than
basal) of purified PLC--EF-RA2 by a maximally effective con-
centration of purified lipidated K-Ras varied with different pro-
tein preparations and experiments but was similar to that
observed with a maximally effective concentration of purified
lipidated RhoA (Fig. 4, middle panel) tested under the same
assay conditions. Increases in enzyme activity also were
observed in some experiments with GDP-bound K-Ras or
RhoA. However, this activity was always much less than that
observed in the presence of GTPS, and also occurred with
purified lipidated Rac1, although no GTPS-dependent activa-
tion of PLC- is observed with this GTPase (34). In contrast to
results obtained with lipidated RhoA or K-Ras, soluble forms of
these GTPases purified from bacteria did not activate PLC--
EF-RA2 (data not shown).
RhoAandK-Ras InteractwithDistinct Regions of PLC- for Its
Regulation—The interaction and regulation in intact cells of
PLC- with Ras family GTPases (27–30, Fig. 2), but not that
FIGURE 2. Activation of PLC- by RhoA and H-Ras requires unique regions
of interaction. A, specific PLC- constructs used and amino acid ranges were
as follows: CDC25-Ct, 509 –2281; CDC25-RA1, 509 –2113; EF-RA2, 1198 –2215;
EF-Ct, 1198 –2281; EF-Ct-Y, 1198 –2281 lacking residues 1667–1728 (white
box); and EF-Ct-linker, 1198 –2281 lacking residues 1532–1641. Note that
the two mutants, CDC25-Ct and CDC25-RA1, only contain part of the
sequences of the CDC25 domain; and similarly, the four mutants, EF-RA2,
EF-Ct, EF-Ct-Y, EF-Ct-linker, only contain part of the sequences of the EF-
hand domains. B, expression vectors (30 ng) for constitutively active mutants
of RhoA(63L) or H-Ras(61L) were expressed in COS-7 cells in the absence or
presence of the indicated PLC- constructs (50 ng each of vectors for CDC25-
Ct, CDC25-RA1, and EF-Ct-Y; and 0.1 ng of vector for EF-Ct-linker).
[3H]Inositol phosphate accumulation was quantified as described under
“Experimental Procedures.” [3H]Inositol phosphate accumulation observed
with empty vector alone was subtracted from the corresponding samples
expressing PLC-. The data shown are the mean  S.D. for triplicate samples
and are representative of results from three or more experiments in each case.
FIGURE 3. Direct activation of PLC- by K-Ras. K-Ras was purified from
detergent-extracted HighFive insect cell membranes as described under
“Experimental Procedures,” was reconstituted at various concentrations in
phospholipid vesicles containing [3H]PtdIns(4,5)P2 and was incubated with
10 M GDP (open circles) or 10 M GTPS (closed circles) for 30 min at 30 °C. The
assay was initiated by the addition of purified PLC--EF-RA2 (2 ng) and incu-
bations were continued for 8 min at 30 °C. The results are the mean  S.E. of a
representative experiment performed six times.
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observed with Rho (33, 34), is dependent on the second RA
domain near the C terminus of PLC-. To illustrate that PLC-
is directly regulated through distinct interactions of the enzyme
with K-Ras and RhoA, a double mutation in the second RA2
domain of PLC--EF-RA2(KE), previously shown to inhibit
activation of PLC- by Ras GTPases in intact cells (29, 30, 33),
was introduced into thewild-type PLC--EF-RA2, and this con-
struct was purified to homogeneity after expression from a
baculovirus in insect cells (Fig. 4, top panel). This double muta-
tion in the RA domain of PLC- results in a charge reversal of
lysine residues 2150 and 2152, creating a negatively charged
surface potential expected to repel the negatively charged
potential of Ras family switch regions. Additionally, Lys-2150
recently was shown to form contacts with switch I of H-Ras
(40).
Basal phospholipase C activity observed with purified PLC-
-EF-RA2(KE) was similar to that observed with wild-type
PLC--EF-RA2 within the range of error over three individual
experiments (Fig. 4, middle and bottom panel). In contrast to
wild-type PLC--EF-RA2, PLC--EF-RA2(KE) retained stim-
ulation by GTPS-bound RhoA, but enzyme activity was not
increased by a concentration ofGTPS-boundK-Ras thatmax-
imally stimulated wild-type PLC--EF-RA2 (Fig. 4, bottom
panel). Moreover, a wide range of concentrations of GTPS-
bound K-Ras failed to activate PLC--EF-RA2(KE) (data not
shown).
Dual Regulation of PLC- by RhoA and K-Ras—Results from
experiments described above confirm that PLC- is directly
regulated by both RhoA and K-Ras in a GTPS-dependent
manner through interactions with distinct regions of the
isozyme. To test whether a combination of the two GTPases
increases the activity of PLC- above that observedwith a single
GTPase, RhoA, and K-Ras were co-reconstituted in the same
phospholipid vesicle preparation, and the phospholipase activ-
ity of purified PLC--EF-RA2 was assessed. Maximally activat-
ing concentrations (300 nM) of either RhoA or K-Ras preloaded
with GTPS resulted in 2.5-fold increases in enzyme activity
over that observed with PLC- alone (Fig. 5, Table 1). When
maximally activating concentrations of RhoA (300 nM) and
K-Ras (300 nM) were combined in the same vesicles, the enzy-
matic rate of PLC--EF-RA2 was approximately additive rela-
tive to the stimulation observed with RhoA or K-Ras individu-
ally (Fig. 5). Inositol lipid hydrolysis was linear for at least 6min
under the assay conditions utilized.
To further assess the regulation of PLC- by both RhoA
and K-Ras, each GTPase was reconstituted in combination
over a wide range of concentrations in phospholipid vesicles
(Fig. 6). Enzyme activity of purified PLC- was increased in a
concentration-dependent manner by GTPS-bound RhoA or
FIGURE 4. Distinct regions of PLC- are required for its activation by RhoA
and K-Ras. Purified proteins (top panel) corresponding to PLC--EF-RA2, PLC-
-EF-RA2(KE), RhoA, and K-Ras were resolved by SDS-PAGE, and gels were
stained with Coomassie Blue. Wild-type PLC--EF-RA2 (middle panel) or
PLC--EF-RA2(KE) (bottom panel) were incubated with phospholipid
vesicles containing [3H]PtdIns(4,5)P2 substrate. Assays were performed
with vesicles in the absence of G-proteins (dashed bars) or in the presence
of GDP-bound (open bars) or GTPS-bound (black bars) RhoA (300 nM) or
K-Ras (300 nM). G-proteins were preincubated in the presence of 10 M
GDP or 10 M GTPS for 30 min at 30 °C to allow nucleotide exchange.
Assays were initiated by the addition of PLC enzyme (2 ng) and incuba-
tions were for 8 min at 30 °C. Data are presented as the mean  S.E. of an
individual experiment, and the results are representative of those
observed in three individual experiments.
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K-Ras. Under these assay conditions, RhoA (20 nM) and K-Ras
(15nM)exhibitedsimilarEC50values foractivationofPLC--EF-
RA2.The same concentration range of RhoAwas examined in the
presence of a maximally activating concentration of K-Ras. The
resulting activity was essentially additive and little or no change
was observed in the EC50 of RhoA (Fig. 6A). In contrast to the lack
of effect of K-Ras on the RhoA activation curve, the presence of
300 nM RhoA resulted in a 3-fold decrease (p  0.01) in the EC50
observed forK-Ras (Fig. 6B andTable 1). Thus, dual, independent,
and additive activation of PLC- occurs in response to purified
RhoA and K-Ras. Activation of PLC- by RhoA also results in an
increase in sensitivity to activation by K-Ras.
DISCUSSION
More than 150 Ras superfamily GTPases promote multifari-
ous cell signaling pathways, but few examples exist of regula-
tion of single effector proteins by GTPases from multiple
GTPase subfamilies. The current work confirms that PLC- is a
unique G protein-regulated effector that is stimulated by both
Ras and Rho GTPases acting by direct interaction with distinct
regions of the isozyme.
This work together with previous studies places PLC- at a
unique point of convergence for the remarkably broad range of
signaling pathways that promote Rho and Ras GTPase-medi-
ated signaling. For example, receptor-mediated activation of
heterotrimeric G proteins results in activation of Rho GTPases
by both G12/13-activated (41) (e.g. p115RhoGEF) and Gq-
activated (42, 43, 44) (e.g.p63RhoGEF)RhoGEFs, and at least 70
other RhoGEFs, regulated by many different upstream regula-
tors, exist (45). The activating proteins and pathways upstream
of Ras also are legion (46). Our data obviously do not establish
whether Rho and Ras simultaneously exist in an activated state
in a cellular membrane microenvironment where PLC- is
commonly and simultaneously activated by both GTPases.
However, these results illustrate that spatial and temporal con-
vergence of activated Rho andRaswould result in lipase activity
that is essentially additive over that occurring with either
GTPase alone. It also will be important to place our observation
of Rho-promoted increases in sensitivity of PLC- to activation
by K-Ras in a physiologically relevant context.
Our studies also did not address the activity of the CDC25
guanine nucleotide exchange domain of the N terminus of
PLC-, and the function of this domain remains unclear. Per-
FIGURE 5. Time course of PtdIns(4,5)P2 hydrolysis by purified PLC- in the
combined presence of RhoA and K-Ras. The time-dependent stimulation of
purified, wild-type PLC--EF-RA2 (1 ng) was tested in phospholipid vesicles
reconstituted with 300 nM RhoA (closed upward triangles) or K-Ras (closed
downward triangles), or vesicles containing 300 nM of both RhoA and K-Ras
(closed circles). GTPases reconstituted in phospholipid vesicles were preincu-
bated in the presence of 10 M GTPS for 30 min at 30 °C to allow nucleotide
exchange. The activity of PLC--EF-RA2 in the absence of G proteins also is
shown (closed squares). The ability of GDP-bound RhoA (open upward trian-
gles), K-Ras (open downward triangles), or RhoA and K-Ras (open circles) to
regulate PLC--EF-RA2 activity are indicated at the 6 min time point. These
results are representative of results from five individual experiments and are
presented as the mean  S.E.
FIGURE 6. Dual and independent regulation of PLC- by purified RhoA
and K-Ras. A, increasing concentrations of RhoA were reconstituted in phos-
pholipid vesicles containing [3H]PtdIns(4,5)P2 in the absence (open circles) or
presence of 300 nM K-Ras (closed circles). After a 30-min preincubation of RhoA
or RhoA and K-Ras containing vesicles in the presence of 10 M GTPS, PLC-
EF-RA2 (2 ng) was added, and the incubation was continued for 8 min at 30 °C.
B, increasing concentrations of K-Ras were reconstituted in phospholipid ves-
icles in the absence (open circles) or presence of 300 nM RhoA (closed circles).
Assay was performed for 8 min at 30 °C. Purified PLC- EF-RA2 also was
added to phospholipid vesicles containing maximally activating concen-
trations of RhoA and K-Ras preloaded with GDP (asterisk). The results are
representative of those from three individual experiments and are pre-
sented as the mean  S.E.
TABLE 1
RhoA and K-Ras regulation of PLC--EF-RA2 activity
Rate EC50
pmol/min/ng nM
PLC--EF-RA2 5.3  0.2
RhoAa 13.7  0.2 21.3  3.4b
RhoA  K-Rasc 21.1  1.0 19.3  0.5b
K-Rasd 13.6  0.3 14.9  2.6e
K-Ras  RhoAf 21.1  1.0 5.6  0.7e
a A concentration effect curve was generated for RhoA alone. The rate indicated is
that observed for a maximally effective concentration K-Ras (300 nM) plus 300 nM
RhoA.
b An EC50 value was determined for RhoA in the absence or presence of 300 nM
K-Ras. No statistically significant difference (p  0.05) was observed.
c A concentration effect curve was generated for RhoA in the presence of 300 nM
K-Ras. The rate indicated is that observed for a maximally effective concentration
of RhoA (300 nM) plus 300 nM K-Ras.
d A concentration effect curve was generated for K-Ras alone. The rate indicated is
that observed for a maximally effective concentration of K-Ras (300 nM).
e An EC50 value was determined for K-Ras in the absence or presence of 300 nM
RhoA. An approximately three-fold increase in potency of K-Ras was observed in
the presence of RhoA (p  0.01).
f A concentration effect curve was generated for K-Ras in the presence of 300 nM
RhoA. The rate indicated is that observed for a maximally effective concentration
of K-Ras (300 nM) plus 300 nM RhoA.
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haps activation of PLC- by Rho causes unique downstream
engagement of Ras GTPases or promotes a feed-forward loop
and additional activation of the phospholipase C by enhanced
activation of Ras, Rap, or other Ras subfamily GTPases, which
in turn associate with PLC- through the RA2 domain. Alter-
natively, PLC- may be sequentially trafficked to specific mem-
brane environments as a consequence of Rho-promoted activa-
tion of Ras GTPases. Citro et al. (47) recently illustrated that
PLC- functions as a nexus in Rho- and Rap-promoted astro-
cyte proliferation. Thus, activation of a thrombin receptor
results in activation of Rho, presumably through activation of a
G12/13-activated RhoGEF. Rho in turn stimulates both the
lipase activity of PLC- and the function of the enzyme as a
guanine nucleotide exchange factor for Rap1. ERK is conse-
quentially activated, and astrocyte mitogenesis ensues.
The mechanism(s) by which Rho and Ras activate PLC- is
unclear. Our studies indicate that lipidation of theseGTPases is
essential for activation of PLC- since increases in activity of the
isozyme were not observed with bacterially expressed soluble
GTPases. These observations in turn suggest that activated
GTPases recruit PLC- to phosphoinositide substrate-contain-
ingmembrane surfaces and therein promote increased enzyme
activity. Other potential mechanisms of PLC- regulation by
Ras superfamilyGTPases include promotion of conformational
changes within the enzyme upon binding of activatedGTPases.
Bunney et al. (40) have proposed a mechanism of regulation of
PLC- whereby the RA domains fold back onto the catalytic
regions of the enzyme to effect autoinhibition, which is relieved
upon binding to Ras and translocation to the plasma mem-
brane. In addition, we previously identified a conserved stretch
of70 amino acids found in theY-region of the catalytic core of
PLC- of all species but not found in other PLC isozymes (30,
34). The unique regulation of PLC- by Rho suggested that this
PLC--specific region is important for Rho-mediated activa-
tion, which indeed has proven to be the case. Thus, Rho binds in
the catalytic core of the isozyme.Whether this simply results in
membrane recruitment of PLC-, or rather results in a confor-
mational change of the active site is yet to be resolved.
The aforementioned possibilities should be considered in
face of recent structural and mechanistic insight into GTP-de-
pendent activation of PLC-2 by Rac. Rac binds PLC-2
through interactionwith the PHdomain (14, 15), and the struc-
ture of holo-PLC-2 superimposes with the structure of
PLC-2 in a GTPS-promoted complex with Rac1 (39). Thus,
binding to Rac1 has no effect on the catalytic core of PLC-2,
but rather, results in membrane localization and orientation of
the catalytic region of PLC-2 in a position that facilitates
increased access to substrate. These structures of PLC-2 also
revealed that an ordered region of the otherwise disordered
linker that separates the two halves, i.e. the X- and Y-regions, of
theTIMbarrel, occludes the active site and therein autoinhibits
the isozyme. Existence of dense negative charge in the X/Y-
linker region of this and other PLC isozymes suggests a unifying
mechanism of regulation of catalysis whereby autoinhibition is
removed when the negatively charged X/Y-linker encounters
the negative surface of the plasma membrane. This model pre-
dicts that removal of the X/Y-linker should activate the
enzyme, as we recently illustrated for PLC-2 as well as for
PLC-1 and PLC- (39). We show here that PLC- lacking the
X/Y-linker region retains regulation by RhoA and K-Ras, and
therefore, binding of neither GTPase requires this region of the
enzyme.
The large size of PLC- allows the enzyme to bind various
GTPases through distinct regions and implies that the binding
of either GTPase alone would not affect the binding of a com-
plimentary GTPase at a more distant site. Enzyme activity in
the simultaneous presence of both GTPases is additive, but
activation of PLC- by RhoA also increases the sensitivity to
activation by K-Ras. Taken together, our data suggest that
RhoA binding to PLC- orients the enzyme at themembrane in
a favorable position for K-Ras to bind the RA2 domain of
PLC-. Alternatively, binding of RhoA within the catalytic core
of PLC- relieves an inhibitory constraint provided by a poten-
tial interaction of the RA domains with the catalytic core of the
enzyme as suggested by Bunney et al. (40). Our data clearly
illustrate that the binding of Rho or Ras GTPases to PLC- are
mutually independent events, and we favor the idea that activa-
tion occurs as a consequence of GTPase-promoted increases in
membraneassociationandproductiveorientationforpolyphos-
phoinositide hydrolysis.
Two decades ago, two groups independently suggested a role
for Ras family proteins in the regulation of phosphoinositide
metabolism (48, 49). The identification of PLC- as a direct and
dual effector of Rho and Ras adds a new level of complexity to
the role of Ras superfamily proteins in phospholipid signaling
and metabolism. Appreciation of the importance of PLC- in
cardiac development and function has followed from the work
of Smrcka (50, 51) and Kataoka (52, 53) and their colleagues.
Hildebrandt and co-workers (54) recently discovered that epi-
thelial cell PLC- plays a crucial role in human kidney podocyte
and glomeruli development, and early onset nephrotic syn-
drome occurs in children with truncating mutations of the
PLC- gene. It will be important to establish to what extent
coordinate, and perhaps cooperative, regulation of PLC- by
Rho and Ras occurs in development and function of the heart,
kidney, and other tissues. Future experiments also will eluci-
date the spatial and temporal regulation of PLC- by multiple
GTPase signaling pathways, andwill provide structurally-based
mechanistic understanding of the regulation of this isozyme by
Ras superfamily GTPases.
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